Trajan Wealth LLC Invests $35.27 Million in IQVIA Holdings Inc. $IQV

Trajan Wealth LLC acquired a new stake in IQVIA Holdings Inc. (NYSE:IQV) during the 2nd quarter, Holdings Channel.com reports. The firm acquired 182,515 shares of the medical research company’s stock, valued at approximately $35,266,000. IQVIA comprises approximately 1.3% of Trajan Wealth LLC’s portfolio, making the stock its 21st largest position.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in the stock. BlackRock Inc. acquired a new position in IQVIA in the 2nd quarter valued at about $2,811,292,000. Boston Partners purchased a new stake in shares of IQVIA during the third quarter worth about $676,698,000. Norges Bank acquired a new position in shares of IQVIA in the fourth quarter valued at approximately $497,445,000. Victory Capital Management Inc. raised its position in shares of IQVIA by 2,628.1% in the fourth quarter. Victory Capital Management Inc. now owns 1,675,479 shares of the medical research company’s stock valued at $377,670,000 after buying an additional 1,614,063 shares during the last quarter. Finally, Orbis Allan Gray Ltd lifted its stake in shares of IQVIA by 96.5% during the fourth quarter. Orbis Allan Gray Ltd now owns 1,901,091 shares of the medical research company’s stock valued at $428,525,000 after buying an additional 933,554 shares during the period. Hedge funds and other institutional investors own 89.62% of the company’s stock.

Insider Activity at IQVIA

In other news, insider W Richard Staub sold 5,500 shares of the business’s stock in a transaction dated Monday, August 3rd. The shares were sold at an average price of $232.68, for a total value of $1,279,740.00. Following the completion of the sale, the insider owned 13,312 shares of the company’s stock, valued at approximately $3,097,436.16. The trade was a 29.24% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Bhavik Patel sold 1,855 shares of the company’s stock in a transaction that occurred on Friday, July 31st. The shares were sold at an average price of $235.27, for a total value of $436,425.85. Following the sale, the insider directly owned 1,348 shares in the company, valued at approximately $317,143.96. This represents a 57.91% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 12,913 shares of company stock worth $3,098,793 over the last three months. 1.70% of the stock is owned by corporate insiders.

Analysts Set New Price Targets

Several research analysts have weighed in on IQV shares. TD Cowen boosted their price target on IQVIA from $233.00 to $288.00 and gave the company a “buy” rating in a report on Wednesday, July 29th. Morgan Stanley reaffirmed an “equal weight” rating and issued a $200.00 price objective (down from $225.00) on shares of IQVIA in a research report on Wednesday, June 17th. HSBC reiterated a “buy” rating and issued a $240.00 target price on shares of IQVIA in a research note on Monday, July 6th. Deutsche Bank Aktiengesellschaft set a $240.00 price target on IQVIA in a research note on Thursday, July 9th. Finally, BMO Capital Markets lifted their price target on IQVIA from $210.00 to $270.00 and gave the company an “outperform” rating in a report on Wednesday, July 29th. One research analyst has rated the stock with a Strong Buy rating, thirteen have given a Buy rating and three have issued a Hold rating to the stock. Based on data from MarketBeat.com, IQVIA has a consensus rating of “Moderate Buy” and a consensus price target of $241.88.

IQVIA Stock Performance

Shares of NYSE:IQV opened at $260.30 on Tuesday. The business has a 50-day moving average of $214.97 and a two-hundred day moving average of $187.62. The firm has a market capitalization of $42.85 billion, a PE ratio of 32.30, a P/E/G ratio of 2.21 and a beta of 1.18. The company has a debt-to-equity ratio of 2.18, a current ratio of 0.71 and a quick ratio of 0.71. IQVIA Holdings Inc. has a 12 month low of $154.50 and a 12 month high of $261.88.

IQVIA (NYSE:IQV) last posted its earnings results on Tuesday, July 28th. The medical research company reported $3.15 earnings per share for the quarter, beating the consensus estimate of $3.03 by $0.12. IQVIA had a net margin of 8.10% and a return on equity of 30.25%. The business had revenue of $4.37 billion for the quarter, compared to analyst estimates of $4.30 billion. During the same quarter in the previous year, the business posted $2.81 EPS. The business’s quarterly revenue was up 8.7% on a year-over-year basis. IQVIA has set its FY 2026 guidance at 12.800-13.000 EPS. As a group, research analysts forecast that IQVIA Holdings Inc. will post 11.57 earnings per share for the current year.

IQVIA announced that its board has approved a share repurchase program on Thursday, May 7th that allows the company to repurchase $2.00 billion in outstanding shares. This repurchase authorization allows the medical research company to purchase up to 6.8% of its stock through open market purchases. Stock repurchase programs are often a sign that the company’s board of directors believes its shares are undervalued.

About IQVIA

IQVIA (NYSE: IQV) is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real‑world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.

IQVIA’s principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real‑world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.